Simcere Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Simcere Pharmaceutical Group has a total shareholder equity of CN¥6.9B and total debt of CN¥1.0B, which brings its debt-to-equity ratio to 14.5%. Its total assets and total liabilities are CN¥11.7B and CN¥4.8B respectively. Simcere Pharmaceutical Group's EBIT is CN¥935.6M making its interest coverage ratio -97.9. It has cash and short-term investments of CN¥3.1B.
Key information
14.5%
Debt to equity ratio
CN¥1.00b
Debt
Interest coverage ratio | -97.9x |
Cash | CN¥3.06b |
Equity | CN¥6.91b |
Total liabilities | CN¥4.80b |
Total assets | CN¥11.71b |
Recent financial health updates
No updates
Recent updates
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing
Jul 29Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market
Dec 29Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates
Aug 28Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?
Jun 03Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically
Apr 06Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)
Jan 10With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case
Aug 16Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18
Jun 27Financial Position Analysis
Short Term Liabilities: 2096's short term assets (CN¥6.4B) exceed its short term liabilities (CN¥3.1B).
Long Term Liabilities: 2096's short term assets (CN¥6.4B) exceed its long term liabilities (CN¥1.7B).
Debt to Equity History and Analysis
Debt Level: 2096 has more cash than its total debt.
Reducing Debt: 2096's debt to equity ratio has reduced from 165.4% to 14.5% over the past 5 years.
Debt Coverage: 2096's debt is not well covered by operating cash flow (15.1%).
Interest Coverage: 2096 earns more interest than it pays, so coverage of interest payments is not a concern.